MBX Biosciences, Inc. Common Stock (MBX)

MBX Biosciences, Inc. Common Stock (MBX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.5B; returns 1 day -3.9%, 1 week -2.2%, 1 year +200.7%.

MBX Biosciences, Inc. (MBX) is a clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapies for endocrine and metabolic disorders. The company has no approved products and generates zero revenue from product sales, relying entirely on cash reserves from financing activities to fund operations and clinical trials.

Groups MBX belongs to

• Clinical Stage Biopharma
• Biotechnology
• Metabolic Disorders
• Endocrinology
• Healthcare
• Biopharmaceutical
• Clinical Stage Biotech
• Clinical Stage
• Life Sciences
• Weight Management
• GLP-1 Agonists
• Pharmaceuticals

MBX financial model: income statement, cash flow and balance sheet